Key Highlights

  • Revenue was USD 2.391 billion, declining 1% on both a reported and organic operational basis.
  • Adjusted EPS was USD 1.75, up 1%, and adjusted Net Income was USD 720 million.
  • Adjusted gross Margin was 71%, down 30 basis points reported and 60 basis points on an operational basis.
  • Full year Revenue guidance was narrowed to the high end of its range, with margin in line or better.

Zoetis Inc. (NYSE:ZTS) reported third quarter 2026 revenue of USD 2.391 billion versus USD 2.422 billion a year earlier, a decline of 1% on both a reported and organic operational basis, driven by a 1% price decline and flat volume. Net income attributable to Zoetis was USD 591 million versus USD 721 million.

Chief Executive Officer Kristin Peck said the quarter was in line with expectations and gave the company confidence to update its full year guidance. Adjusted EPS of USD 1.75 was up 1%, driven by a lower share count from ongoing share repurchases.

Segment and Franchise Results

The U.S. segment generated revenue of USD 1.2 billion, down 6%, on declines in companion animal from the key dermatology portfolio and the impact of generics on certain brands. The international segment was USD 1.1 billion, up 4%, with growth across livestock, parasiticides and osteoarthritis pain more than offsetting dermatology headwinds.

Companion animal revenue declined 5% to USD 1.6 billion, with an 8% decline in the U.S. Key dermatology declined 16% globally on USD 396 million in sales, reflecting competitive headwinds and pricing actions. In the U.S., dermatology declined 13% on USD 266 million, driven by share loss in Apoquel, slowed by promotional investments, with the chewable formulation now about half of Apoquel volume. Cytopoint sales also declined, reflecting canine visit declines of approximately 5%, with pruritic visits down 3%.

The Simparica franchise grew 1% on USD 358 million globally, with international up 10% on USD 99 million and the U.S. down 2% on USD 259 million. Osteoarthritis pain medicines generated USD 137 million, up 2%, and the launches of Lenivia and Portela in the EU and Canada drove 13% international growth on USD 86 million. Companion animal diagnostics delivered USD 122 million, up 13% globally.

Margins and Guidance

Adjusted gross margin was 71%, down 30 basis points reported and 60 basis points on an operational basis, which management attributed to strategic pricing initiatives, product mix and certain inventory-related charges, partly offset by refunds related to prior Tariff assessments. Adjusted net income was down 7% on an organic operational basis.

Management said the full year margin is shaping up in line with or better than its expectations and that it narrowed full year revenue guidance to the high end of its range. For nine months, revenue was USD 7.121 billion versus USD 7.094 billion, and net income attributable to Zoetis was USD 1.883 billion versus USD 2.049 billion.

Pipeline and Market Factors

The company cited the approval of long-acting Cytopoint in the fourth quarter, which adds a more convenient option in chronic itch, a segment accounting for more than 60% of global dermatology doses.

Disclosed variables include canine visit trends, affordability pressures on pet owner spending, competition in dermatology, the Simparica transition toward Simparica Trio and the pace of Lenivia and Portela launches.